Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 1/2019

03.01.2019 | Original Article

Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review

verfasst von: Paul H. Sugarbaker

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation versus an aggressive approach using cytoreductive surgery (CRS) and hyperthermic perioperative intraperitoneal chemotherapy (HIPEC) must be made. This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, prevention of peritoneal metastases may be an option. The clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur. Peritoneal metastases should always be considered by the multidisciplinary team for treatment or prevention.
Literatur
1.
Sugarbaker PH (2006) New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 7(1):69–76CrossRefPubMed
2.
Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M (2016) Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract 12(10):928–935CrossRefPubMed
3.
4.
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 33:1460–1466CrossRefPubMedPubMedCentral
5.
Sugarbaker PH, Kwong ML. Regional chemotherapy: possibilities for prevention and treatment of peritoneal metastases from gastric cancer. (In) Management of gastric cancer. SMGroup at www.​smgbooks.​com
6.
Goere D, Passot G, Gelli M, Sugarbaker PH, Glehen O (2017) Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperth 33:528–533CrossRef
7.
Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 63:364–367CrossRefPubMed
8.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed
9.
Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550CrossRefPubMed
10.
Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardowski ZJ, Pyle WK (1978) Continuous ambulatory peritoneal dialysis. Ann Intern Med 88:449–456CrossRefPubMed
11.
Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 40:634–656CrossRef
12.
Torres IJ, Litterst CL, Guarino AM (1978) Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330–340CrossRefPubMed
13.
Dedrick RL, Myers CE, Bungay PM, de Vita V Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11PubMed
14.
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT Jr, Myers CE (1980) Phase 1 and pharmacologic studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567–572PubMed
15.
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922PubMed
16.
Jones RB, Myers CE, Guarino AM et al (1978) High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol 1:161–166CrossRefPubMed
17.
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC (1979) Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214PubMed
18.
McVie JG, Dikhoff T, Van der Heide J et al (1985) Tissue concentration of platinum after intraperitoneal cisplatinum in patients. Proc Am Assoc Cancer Res 26:162
19.
Sugarbaker PH, van der Speeten K (2016) Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 7(1):29–44PubMedPubMedCentral
20.
Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH (2011) Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68:147–156CrossRefPubMed
21.
Shiu MH, Fortner JG (1980) Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res 40:4081–4084PubMed
22.
Meyer JL, Kapp DS, Fessenden P, Hahn GH (1989) Hyperthermic oncology: current biology, physics and clinical results. Pharmac Ther 42:251–288CrossRef
23.
Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260PubMed
24.
Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y (1980) Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 44:1840–1842
25.
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, et al (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. 61:232–237
26.
Fujimura T, Yonemura Y, Muraoka K, Takamura H, Hirono Y, Sahara H, Ninomiya I, Matsumoto H, Tsugawa K, Nishimura GI, Sugiyama K, Miwa K, Miyazaki I (1994) Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 18:150–155CrossRefPubMed
27.
Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T (1998) Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85:529–534CrossRef
28.
Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14(10):2702–2713CrossRefPubMed
29.
Feingold PL, Kwong MLM, Sabesan A, Sorber R, Rudloff U (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol 7:87–98PubMedPubMedCentral
30.
Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 48:1776–1782PubMed
31.
32.
Quirke P, Sebag-Montefiore D, Steele R et al (2006) Local recurrence after rectal cancer resection is strongly related to the plane of the surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. J Clin Oncol vol. 24, article 3512
33.
Heald RJ, Ryall RDH (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1(8496):1479–1482CrossRefPubMed
34.
West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P (2010) Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 28(2):272–278CrossRefPubMed
35.
Sugarbaker PH (2013) Colorectal cancer metastases, a surgical perspective. Surg Oncol Clin N Am 22(2):289–298CrossRefPubMed
36.
Honore C, Gelli M, Francoul J et al (2017) Ninety percent of the adverse outcomes in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperth 33(5):505–510CrossRef
37.
Honore C, Goere D, Souadka A, Dumont F, Elias D (2013) Definition of patient presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 20:183–192CrossRefPubMed
38.
Cunliffe WJ, Sugarbaker PH (1989) Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). Br J Surg 76:1082–1090CrossRefPubMed
39.
Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P (1990) Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies. Cancer Res 50:5790–5794PubMed
40.
Sugarbaker PH (1999) Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 43(Suppl):S15–S25CrossRefPubMed
41.
Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 55:130–138CrossRefPubMed
42.
Pestieau SR, Sugarbaker PH (2000) Treatment of primary colon cancer with peritoneal carcinomatosis: a comparison of concomitant versus delayed management. Dis Colon Rectum 43:1341–1348CrossRefPubMed
43.
Tentes AA, Spiliotis ID, Korakianitis OS, Vaxevanidou A, Kyziridis D (2011) Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results. ISRN Surg 2011:529876CrossRefPubMedPubMedCentral
44.
Noura S, Ohue M, Shingai T, Kano S, Ohigashi H, Yano M, Ishikawa O, Takenaka A, Murata K, Kameyama M (2011) Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol 18:396–404CrossRefPubMed
45.
Braam HJ, Boerma D, Wiezer MJ, Ramshorst v (2013) Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. Eur J Surg Oncol 39:988–993CrossRefPubMed
46.
Sammartino P, Sibio S, Accarpio F, Di Giorgio A (2014) Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Color Dis 29:1081–1089CrossRef
47.
Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH (2001) Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25:985–990CrossRefPubMed
48.
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, de Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292CrossRefPubMed
49.
Sugarbaker PH, van der Speeten K, Stuart OA, Chang D, Mahteme H (2012) Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. Cine-Med Publishing, Woodbury, pp 183–206
50.
51.
Sugarbaker PH, Sammartino P, Tentes AA (2012) Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer 1(2):115–123CrossRef
52.
Sammartino P, Tentes AA, Sugarbaker PH (2015) Eradication of minimal residual disease in the perioperative period in primary colorectal cancer. Colorectal Cancer 4:157–166CrossRef
53.
Sammartino P, Societa Italiana di Chirurgia Oncologica (SICO). PROMENADE Trial (PROactive Management of ENdoperitoneal spreAD in colonic cancer). [cited 2017 September 19]
54.
Griffen WO, Humphrey L, Sosin H (1969) The prognosis and management of recurrent abdominal malignancies. Curr Probl Surg 6:1–43CrossRef
55.
Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, Fletcher WS, Cruz AB, Gatchell FG, Oviedo M, Meyer KK, Leffall LD, Berk RS, Stewart PA, Kurucz SE (1985) Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 55:1284–1290CrossRefPubMed
56.
57.
Elias D, Goere D, Di Pietrantonio D et al (2008) Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 247(3):445–450CrossRefPubMed
58.
Delhorme JB, Triki E, Romain B, Meyer N, Rohr S, Brigand C (2015) Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg 152(3):149–154CrossRefPubMed
59.
Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer, rationale and report of early data. Int J Surg Oncol Volume 2011, Article ID 161862, 7 pages, https://​doi.​org/​10.​1155/​2011/​161862
60.
61.
Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389–394CrossRefPubMed
62.
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221(2):124–132CrossRefPubMedPubMedCentral
63.
Sethna KS, Sugarbaker PH (2004) New prospects for the control of peritoneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy. Cancer Therapy 2:79–84
64.
Sugarbaker PH (2005) Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Investig 23:155–172CrossRef
65.
Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15(1):49–58
66.
da Silva RG, Sugarbaker PH (2006) Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 203(6):878–886CrossRefPubMed
67.
Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRefPubMed
68.
Lampe B, Kroll N, Piso P, Forner DM, Mallman P (2015) Prognostic significance of Sugarbaker’s peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer 25:135–144CrossRefPubMed
69.
Sugarbaker PH, Yan TD, Stuart OA, Yoo D (2006) Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32(6):686–691CrossRefPubMed
70.
Sugarbaker PH, Chang D (2017) Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 43(7):1228–1235CrossRefPubMed
71.
Sugarbaker PH (2017) Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas (second edition). Cine-Med Publishers, Woodbury, pp 109–132
72.
Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH (2002) Malignant transformation of “benign” cystic mesothelioma of the peritoneum. J Surg Oncol 79(4):243–251CrossRefPubMed
73.
Ihemelandu C, Sugarbaker PH (2016) Clinicopathologic and prognostic features in patients with peritoneal metastasis from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 23(5):1474–1480CrossRefPubMed
74.
Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P (2006) Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Sur Oncol 32(6):632–636CrossRef
75.
Yan TD, Morris DL, Kusamura S, Baratti D, Deraco M (2008) Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol 98:224–227CrossRefPubMed
76.
Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH (1993) Evaluation of computer tomography in patients with peritoneal carcinomatosis. Cancer 72(5):1631–1636CrossRefPubMed
77.
Koh JL, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333CrossRefPubMed
78.
Sugarbaker PH, Sardi A, Brown G, Dromain C, Rousset P, Jelinek JS (2017) Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. Int J Hyperth 33(5):497–504CrossRef
79.
Jacquet P, Jelinek JS, Chang D, Koslowe P, Sugarbaker PH (1995) Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 181:530–538PubMed
80.
Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 15:839–849CrossRef
81.
Rivard JD, Temple WJ, McConnell YJ et al (2014) Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg 207:760–765CrossRefPubMed
82.
Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455–461CrossRefPubMedPubMedCentral
83.
Goere D, Souadka A, Faron M et al (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964CrossRefPubMed
84.
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31CrossRefPubMed
85.
Sugarbaker PH, Welch L, Mohamed F, Glehen O (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12(3):605–621CrossRefPubMed
86.
Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):275–285CrossRef
87.
Look M, Chang D, Sugarbaker PH (2004) Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14(1):35–41CrossRefPubMed
88.
Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH (1999) Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 35(3):413–419CrossRefPubMed
89.
Paul BK, Ihemelandu C, Sugarbaker PH Prior surgical score: an analysis of the prognostic significance of an initial non-definitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Abstract in diseases of colon and rectum, March 2016
90.
Van der Speeten K, Stuart OA, Sugarbaker PH (2012) Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am 21(4):577–597CrossRefPubMed
91.
Mohamed F, Sugarbaker PH (2003) Intraperitoneal taxanes. Surg Oncol Clin N Am 12(3):825–833CrossRefPubMed
92.
Bakrin N, Bereder JM, Decullier E et al (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 22:1570–1575
93.
94.
Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, el Otmany A, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272CrossRefPubMed
95.
Van Ruth S, Verwaal VJ, Zoetmulder FAN (2003) Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:771–780CrossRefPubMed
96.
Sugarbaker PH, Van der Speeten K, Stuart OA et al (2011) Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol 37:719–726CrossRefPubMed
97.
Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689–701CrossRefPubMed
98.
Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth 23:431–442CrossRef
99.
Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH (1998) Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41:147–154CrossRefPubMed
100.
Young JS, Lumsden CE, Stalker AL (1950) The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol 62:313–333CrossRefPubMed
101.
Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K (1992) Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 52:487–490PubMed
102.
Urano M, Kuroda M, Nishimura Y (1999) Invited review for the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperth 15:79–107CrossRef
103.
Sugarbaker PH, van der Speeten K (2017) An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy. In: Sugarbaker PH (ed) Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas (second edition). Cine-Med Publishers, Woodbury, pp 17–46
104.
Benoit L, Cheynel N, Ortega-Deballon P, Giacomo GD, Chauffert B, Rat P (2008) Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol 15:542–546CrossRefPubMed
105.
Yan TD, Black D, Savady R, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14(2):484–492CrossRefPubMed
106.
Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21(24):4560–4567CrossRefPubMed
107.
Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN (2008) Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 31(1):49–54CrossRefPubMed
108.
Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras AD, Kusamura S (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13(2):229–237CrossRefPubMed
109.
Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN (2005) Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12(1):65–71CrossRefPubMed
110.
Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA (2004) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11(2):178–186CrossRefPubMed
111.
Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: restrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68CrossRefPubMed
112.
Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, Zoetmulder FAN (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743CrossRefPubMed
113.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432CrossRefPubMed
114.
Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24(24):4011–4019CrossRefPubMed
115.
Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR (2004) Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 10:2727–2730CrossRefPubMedPubMedCentral
116.
117.
Bijelic L, Jonson A, Sugarbaker PH (2007) Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 18(12):1943–1450CrossRefPubMed
118.
Elias D, Raynard B, Bonnay M, Pocard M (2006) Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol 32:607–613CrossRefPubMed
Metadaten
Titel
Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review
verfasst von
Paul H. Sugarbaker
Publikationsdatum
03.01.2019
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 1/2019
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-018-0856-1

Weitere Artikel der Ausgabe 1/2019

Indian Journal of Surgical Oncology 1/2019 Zur Ausgabe

Case Report

Neuroendocrine Carcinoma of Duodenum—an Uncommon Tumour at an Unusual Site

Original Article

Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients—a Tertiary Experience

Original Article

Effect of Surgery or Radiotherapy of the Breast on Survival in Metastatic Disease: a Retrospective Cohort Study

Case Report

Squamous Cell Carcinoma Larynx with Malignant Ascites: a Rare Entity

Original Article

Role of Single-Agent Methotrexate as a Neoadjuvant Chemotherapy in Oral Cavity Cancers

Case Report

Ameloblastic Fibrosarcoma in Pregnancy: an Unreported Entity!

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.